Longhaulers phase 2 results should push up the pri

Longhaulers phase 2 results should push up the price given the potential market. I fully expect Brazil interim results to grab us a few EUAs. With 4 doses, an easier to achieve primary endpoint against a worse SOC we should hit stat sig p value even with the smaller patient population.